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ABSTRACT
Objective: The objective of this pilot study was to determine whether glugagon-like peptide 2 (GLP-
2) secretion relates to insulin sensitivity (IS) in obese subjects. Subjects and methods: Twenty four 
obese subjects [body mass index (BMI) 40.0 ± 3.0 kg/m2 (mean ± standard deviation)] were included, 
nine of which were male, age 43 ± 8 years. Twelve subjects had type 2 diabetes, all treated with oral 
anti-diabetic agents only. The subjects were submitted to standard meal tolerance test (MTT) for do-
sage of the curves: glucose, insulin, and GLP-2. Insulin sensitivity was measured by HOMA-IR, and 
OGIS was derived from the MTT. Spearman linear correlations and partial correlations were obtained. 
Results: There was an inverse relationship between the GLP-2 secretion and IS: HOMA-IR correlated 
with GLP-2 AUC (R = 0.504; p = 0.012), and OGIS correlated with GLP-2 incremental AUC (R = -0.54; 
p = 0.054). The correlation persisted after controlling for BMI. Conclusion: We found an association 
of GLP-2 secretion and insulin resistance (IR). The understanding of the underlying mechanisms may 
provide future directions in the pharmacological manipulation of incretins, and in the treatment of 
obesity and related metabolic disorders. Arq Bras Endocrinol Metab. 2013;57(8):632-5
Keywords
GLP-2; insulin resistance; HOMA-IR; OGIS; obese patients
RESUMO
Objetivo: O objetivo deste estudo piloto foi determinar a relação entre a secreção de glugagon like 
peptide 2 (GLP-2) e a sensibilidade insulínica (SI) em indivíduos obesos. Sujeitos e métodos: Vinte 
e quatro indivíduos obesos [IMC 40.0 ± 3.0 kg/m2 (média ± desvio-padrão)] foram incluídos no estu-
do, sendo 9 homens, com idade de 43 ± 8 anos. Do total, 12 indivíduos tinham diabetes tipo 2, todos 
tratados somente com antidiabéticos orais. Os sujeitos foram submetidos ao teste de refeição padrão 
(MTT) para dosagens das curvas: glicose, insulina e GLP-2. A sensibilidade insulínica foi mensurada 
pelos HOMA-IR e OGIS, obtidos pelos valores do MTT. As correlações lineares e correlações par-
ciais foram obtidas. Resultados: Observou-se uma relação inversa entre a secreção de GLP-2 e SI: 
HOMA-IR correlacionou-se com GLP-2 AUC (R = 0,504; p = 0,012) e OGIS correlacionou-se com GLP-2 
incremental AUC (R = -0,54; p = 0,054). A correlação persistiu controlando o IMC. Conclusão: Encon-
tramos uma associação entre a secreção de GLP-2 e a resistência insulínica. A compreensão desses 
mecanismos poderá direcionar o futuro farmacológico da manipulação de incretinas no tratamento 
da obesidade e das desordens metabólicas. Arq Bras Endocrinol Metab. 2013;57(8):632-5
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INTRODUCTION
G lucagon-like peptide-2 (GLP-2) is a hormone co--secreted with glucagon-like peptide-1 from en-
teroendocrine cells in the small and large bowels, also 
expressed in the pancreas and the brain (1,2). GLP-2 
secretion is regulated by food nutrients, mainly fat and 
carbohydrates, and targets receptors in the gastrointes-
tinal tract, from the stomach to the colon. The major 
known action of GLP-2 is mucosal growth, especially in 
the proximal bowel, increasing villous height and crypt 
cell proliferation, and inhibiting apoptosis in both the 
crypt and villous compartments (3).
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The potent intestinotrophic action of GLP-2 results 
in increased nutrient absorption, which justifies inter-
est in potential therapeutic applications in conditions 
of malabsorption and intestinal injury/atrophy, with 
promising initial results (4,5). On the other hand, little 
is known about the role of this hormone in conditions 
related to increased uptake of energy and macronutri-
ents, specially fatty acids, such as obesity and insulin 
resistance (IR). 
Our hypothesis is that insulin sensitivity is influ-
enced by increased absorption of nutrients mediated by 
GLP-2. The objective of this pilot study was to deter-
mine whether GLP-2 secretion relates to insulin sensi-
tivity (IS) in obese subjects.
SUBJECTS AND METHODS
The study was approved by the Institutional Ethics 
Review Board at University of Campinas (Unicamp – 
number: 801/2008). All participants provided written 
informed consent before participation. Twenty four 
obese subjects [body mass index (BMI) 40.0 ± 3.0 kg/m2 
(mean ± standard deviation)] were included, nine of 
which were male, aged 43 ± 8 years. Twelve subjects 
had type 2 diabetes, all treated with metformin and/or 
sulfonylureas only. 
After an overnight fast (12 h), subjects were sub-
mitted to standard meal tolerance test (MTT), based 
in a mixed meal containing 515 kcal (41.8% fat, 40.7% 
carbohydrates, and 17.5% protein). For diabetic sub-
jects, oral antidiabetic drugs were discontinued one day 
before the test. Blood samples were drawn for glucose, 
insulin, and GLP-2 at -15, 0, 30, 45, 60, 90, 120, 150, 
and 180 minutes. Glucose was determined by the glu-
cose oxidase method. For GLP-2 analysis, blood sam-
ples were collected in tubes with EDTA3 plus Sigma di-
protin. Serum samples were stored in a freezer at -80°C 
for posterior analysis of insulin (ELISA, Bayer Corp.) 
and GLP-2 (ELISA, Millipore Corp.).
Statistical methods
The area under the curve (AUC) of GLP-2, glucose 
and insulin were calculated by the trapezoidal method. 
The incremental AUC was calculated as total AUC mi-
nus the area under the basal value.
Insulin sensitivity (IS) was estimated by two me thods: 
(1) the Homeostatic Model Assessment (HOMA-IR) 
from the formula [glucose (mmol/L) X Insulin (µU/
mL)/22.5], for which higher values represent lower IS; 
and (2) the Oral Glucose Insulin Sensitivity (OGIS) 
obtained from MTT, which represents the postprandial 
glucose clearance adjusted for body surface area5, and 
for which higher values represent higher IS.
SSPS 16.0 was used for statistical analyses with 
Spearman linear correlations and partial correlations. 
Statistical significance was assumed if p < 0.05.
RESULTS
The metabolic characteristics of the subjects are pre-
sented in table 1.
Table 1. Metabolic characteristics of the studied subjects
Characteristic Mean ± SD 
Fasting plasma glucose (mg/dL)** 155.5 ± 45.2
Fasting plasma insulin (µg/dL)** 19.5 ± 12.2
HOMA-IR** 6.2 ± 5.5
AUC GLP-2 (ng/mL x min)** 1062.16 ± 204.12
AUCi GLP-2 (ng/mL x min)** 183.2 ± 164
OGIS** 300.5 ± 18.75
HOMA-IR: homeostatic model assessment/insulin resistance; AUC GLP-2: area under the curve 
of glucagon-like peptide 2; AUCi GLP-2: incremental area under the curve of glucagon-like 
peptide 2; OGIS: oral glucose insulin sensitivity.
** Mean ± standard deviation.
Insulin sensitivity (IS) and GLP-2 AUCs were sta-
tistically similar between diabetic and non-diabetic sub-
jects (data not shown).
We observed an inverse relationship between the 
GLP-2 secretion and IS: HOMA-IR correlated with 
GLP-2 AUC (R = 0.504; p = 0.012) (Figure 1), and 
OGIS correlated with GLP-2 incremental AUC (R = 
-0.54; p = 0.054) (Figure 2). The correlation persisted 
after controlling for BMI.
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Figure 1. Relationship between GLP-2 area under the curve (AUC) (ng/mL 
x min) and insulin resistance index (HOMA-IR).
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intestinal IR (14). Second, Cani and cols. (15) demon-
strated that GLP-2 has a protective effect on metabolic 
endotoxemia in mice, demonstrated by lower plasma 
lipopolysaccharide (LPS) and cytokines and decreased 
lipid content and inflammation in the liver. Such effect 
was, at least in part, related to lower intestinal perme-
ability, preventing LPS translocation.
A second hypothesis is that glucagon could be the 
link between GLP-2 and IR. GLP-2 directly stimulates 
glucagon secretion and counteracts the glucagono-
static action of GLP-1 in healthy subjects (9), and in 
type 1 and type 2 diabetic subjects (3,16). Glucagon is 
counter-regulatory to insulin action, increasing glucose 
output and inhibiting glucose uptake in the liver, and 
has been linked to IR in obese subjects with normal or 
impaired glucose tolerance (17,18).
Some limitations of the study are that we have not 
assayed fatty acids and glucagon, and have not evalu-
ated intestinal absorption and histology.
The relationship of GLP-2 and IR should be consid-
ered in future studies of pharmacological use of GLP-2 
and its analogues, especially for potential adverse meta-
bolic events.
We found an association of GLP-2 secretion and IR. 
The understanding of the underlying mechanisms may 
provide future directions in the pharmacological ma-
nipulation of incretins, and in the treatment of obesity 
and related metabolic disorders.
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DISCUSSION
We report, for the first time, an association between 
GLP-2 secretion and IR in obese subjects.
The strength of our finding is the use of two com-
plementary indexes of IS: one based in a fasting basal 
method (HOMA-IR), which measures mainly hepatic 
IS (6); and one that is a postprandial, dynamic method 
(OGIS) that measures whole-body IS (hepatic and pe-
ripheral) (5).
There are some hypotheses to explain this finding. 
The first hypothesis is that GLP-2 induced an increased 
absorption of nutrients, especially fatty acids, which 
could contribute to IR. GLP-2 has an intestinotrophic 
effect in the proximal and distal bowels (7), and has 
acute effects in intestinal fat absorption and lipopro-
tein production, which result in increased postprandial 
circulating triglycerides and free fatty acids in rodents 
(8) and humans (9). Fatty acids are a key factor for IR 
in skeletal muscles and liver by a number of mecha-
nisms: preferential oxidation over glucose; impaired 
insulin signaling and glucose transport; inflammation 
and oxidative stress secondary either to fat metabolites 
(ceramides, diacylglycerol, acyl-CoA) or binding to 
fatty acid receptors (G-coupled protein or peroxisome 
proliferator-activated receptors) (10).
The intestinal microbiota could have a contribution 
to this hypothesis. Food fermentation both increases 
energy harvesting in animal and human obesity (11) 
and produces short-chain fatty acids linked to increased 
expression of pro-enteroglucagon in rodents (12) and 
to proximal and distal bowel hypertrophy (13). 
There are some counterpoints to the discussion 
above. First, we cannot exclude the hypothesis that in-
creased GLP-2 secretion could be a manifestation of 
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